Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
15 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chronic Myeloid Leukemia in the Chronic Phase.
Patients with BCR-ABL-negative checks.
15 years old over.
ECOG performance status (PS) score 0-2.
Adequate organ function (hepatic, renal and lung).
Signed written informed consent.
A case with the double cancer of the activity.
Women who are pregnant or breastfeeding.
Patients with complications or a history of severe.
Patients with mutation of T315I、F317L、V299L.
Patients with additional chromosome abnormalities.
The case of Pleural effusion with poor control.
Patients with a history of hematopoietic stem cell transplantation.